The IgG Receptor FcRn Large Subunit p51 pipeline drugs market research report outlays comprehensive information on the IgG Receptor FcRn Large Subunit p51 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the IgG Receptor FcRn Large Subunit p51 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Immunology, Central Nervous System, Hematological Disorders, and Hormonal Disorders which include the indications Myasthenia Gravis, Autoimmune Disorders, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Demyelinating Diseases, Acquired (Autoimmune) Hemolytic Anemia, Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura), Graves Diseases, and Hashimoto Thyroiditis. It also reviews key players involved in IgG Receptor FcRn Large Subunit p51 targeted therapeutics development with respective active and dormant or discontinued products.
The IgG Receptor FcRn Large Subunit p51 pipeline targets constitutes close to 14 molecules. Out of which, approximately 14 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase I, and Preclinical stages are 4, 1, 4, and 5 respectively.
IgG Receptor FcRn Large Subunit p51 overview
The IgG receptor FcRn large subunit p51 (FCRN) is a cell surface receptor that transfers passive humoral immunity from the mother to the newborn. Binds to the Fc region of monomeric immunoglobulin gamma and mediates its selective uptake from milk. IgG in the milk is bound at the apical surface of the intestinal epithelium. The resultant FcRn-IgG complexes are transcytosed across the intestinal epithelium and IgG is released from FcRn into blood or tissue fluids.
For a complete picture of IgG Receptor FcRn Large Subunit p51’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
